GWA
CLCD

Genesis Wealth Advisors’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Genesis Wealth Advisors’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$480 Buy
+54
New +$463 ﹤0.01% 483

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Genesis Wealth Advisors's CLCD Position: Q2 2015 in Review

Genesis Wealth Advisors opened a new position in CoLucid Pharmaceuticals, Inc. (CLCD) in Q2 2015: 54 shares worth $480. The stake represents ﹤0.01% of the portfolio and ranks #483 among its holdings.

18 funds tracked by Wall St. Rank hold CLCD as of Q2 2015.

  • Genesis Wealth Advisors held 54 shares of CoLucid Pharmaceuticals, Inc. worth $480 as of Q2 2015.
  • CoLucid Pharmaceuticals, Inc. was a new Genesis Wealth Advisors position in Q2 2015.
  • CoLucid Pharmaceuticals, Inc. made up ﹤0.01% of Genesis Wealth Advisors's portfolio in Q2 2015, its #483 holding.
  • 18 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q2 2015.

Based on Genesis Wealth Advisors's 13F filing for Q2 2015, filed 24 Aug 2015.